Last reviewed · How we verify
Adebrelimab injection
Adebrelimab is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 receptors on immune cells.
Adebrelimab is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 receptors on immune cells. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | Adebrelimab injection |
|---|---|
| Also known as | Ai Rui Li, SHR-1316 |
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the PD-L1/PD-1 axis, adebrelimab removes the inhibitory signal that tumors use to evade immune surveillance, allowing T cells and other immune effectors to recognize and attack cancer cells more effectively. This mechanism is similar to other PD-L1 inhibitors and represents a form of immune checkpoint inhibition used in cancer immunotherapy.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Fatigue
- Decreased appetite
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion-related reactions
Key clinical trials
- A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (PHASE2)
- A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (PHASE3)
- A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma (PHASE3)
- Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma (NA)
- A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) (PHASE3)
- Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD (PHASE2)
- HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adebrelimab injection CI brief — competitive landscape report
- Adebrelimab injection updates RSS · CI watch RSS
- Shanghai Hengrui Pharmaceutical Co., Ltd. portfolio CI